Shareholders of Agenus Inc. Should Contact The Gross Law Firm Before November 5, 2024 to Discuss Your Rights – AGEN

Core Viewpoint - The Gross Law Firm is notifying shareholders of Agenus Inc. regarding a class action lawsuit due to allegations of misleading statements related to the effectiveness of their immuno-oncology products [1][2]. Group 1: Allegations - The complaint alleges that during the class period from January 23, 2023, to July 17, 2024, the defendants made materially false and misleading statements about the combination therapy of botensilimab and balstilimab [2]. - It is claimed that the effectiveness of the combination therapy was overstated, leading to inflated expectations regarding clinical results, regulatory, and commercial prospects [2]. - As a result, the company's public statements were deemed materially false and misleading throughout the relevant period [2]. Group 2: Class Action Details - Shareholders who purchased shares of Agenus during the specified class period are encouraged to register for the class action, with a deadline set for November 5, 2024 [2]. - Registration allows shareholders to be enrolled in a portfolio monitoring software that provides updates on the case's status [2]. - There is no cost or obligation for shareholders to participate in this class action [2].